


Supplemental materials for:

Jha MK, Grannemann BD, Trombello JM, et al. A structured approach to detecting and treating depression in primary care: VitalSign6 Project. *Ann Fam Med*. 2019;17(4):326-335.

Supplementary Figure 1. Rates of PHQ-2 positive screen in the 16 primary care clinics

PHQ-2 is Patient Health Questionnaire 2-item scale, PHQ-2 positive was defined as a PHQ-2 score > 2



Supplementary Box 1. Detailed conflicts of interest statement.

Dr. Jha has received contract research funding from Acadia Pharmaceutical and Janssen Research. **Dr. Trombello** currently owns stock in Merck and Gilead Sciences and within the past 36 months previously owned stock in Johnson & Johnson. **Dr. Greer** has received research funding from NARSAD and contracted research support from Janssen Research & Development, LLC. She has received honoraria and/or consultant fees from H. Lundbeck A/S and Takeda Pharmaceuticals International, Inc. **Dr. Rush** has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC, Eli Lilly, Emmes Corp, Johnson and Johnson (Janssen), Liva-Nova, Mind Linc., Sunovion, Takeda USA, Taj Medical; speaking fees from Liva-Nova; and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX. (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. **Dr. Trivedi** has consulted for or served on the advisory board of Alkeremes Inc., Akili Interactive, Allergan Pharmaceuticals, Arcadia Pharmaceuticals, Avanir Pharmaceuticals, Brintellix Global, Bristol Myers Squibb, Caudex, Cerecor, Forest Pharmaceuticals, Global Medical Education Inc, Health Research Associates, Insys, Johnson & Johnson Pharmaceutical Research & Development, Lilly Research Laboratories, Lundbeck Research USA, Medscape, Merck & Co. Inc, Mitsubishi Pharma, MSI Methylation Sciences – PamLab Inc., Navitor, Otsuka America Pharmaceutical Inc., One Carbon Therapeutics, Otsuka America Pharmaceutical Inc., Pfizer Inc, Takeda Global Research; he has received royalties from Janssen Research and Development, LLC; he has author agreements from Janssen Asia Pacific and the Oxford University Press; and he has received grants from Agency for Healthcare Research and Quality (AHRQ), Cancer Prevention and Research Institute of Texas (CPRIT), National Institute of Mental Health (NIMH), National Institute of Drug Abuse (NIDA), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Advancing Translational Sciences (NCATS), Johnson & Johnson, PCORI. **Mr. Grannemann, Dr. Clark, and Ms. Levinson and Lawson** declare no conflicts of interest.